Costo per responder di risankizumab e secukinumab nel trattamento della psoriasi a placche da moderata a grave in Italia

PURPOSE: The objective of this analysis was to compare the cost per responder between risankizumab and secukinumab among patients with moderate-to-severe plaque psoriasis in Italy. METHODS: The clinical efficacy was assessed based on IMMerge study of published efficacy data as measured by Psoriasis...

Descripción completa

Detalles Bibliográficos
Autores principales: Gisondi, Paolo, Loconsole, Francesco, Raimondo, Paola, Ravasio, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616179/
https://www.ncbi.nlm.nih.gov/pubmed/36627874
http://dx.doi.org/10.33393/grhta.2021.2258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616179/
https://www.ncbi.nlm.nih.gov/pubmed/36627874
http://dx.doi.org/10.33393/grhta.2021.2258

Ejemplares similares